--- title: "Aspira Women's Health (AWHL) news: delisting and offering" url: "https://aibio.space/companies/aspira-women-s-health/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AWHL delisting and offering news: Nasdaq panel delists Aspira Women's Health over $2.5 million equity rule. Aspira Women's Health Inc." --- AWHL Aspira Women's Health Inc. OTC · United States # Aspira Women's Health (AWHL) news AWHL delisting and offering news Debt Financing · 2026-07-06 ## [Aspira Women's Health takes $1,050,000 secured subordinated loan](https://aibio.space/news/aspira-womens-health-takes-1-050-000-secured-subordinated-loan/) Aspira Women's Health signed a $1,050,000 secured subordinated note with Agile Lending, LLC as lead lender. The note matures January 26, 2027, and the company will use it to refinance an earlier January loan. ## Latest Aspira Women's Health news 1. 2026-06-17 Company Updates [Aspira Women's Health names interim CEO after Buhle exit](https://aibio.space/news/aspira-womens-health-names-interim-ceo-after-buhle-exit/) Chairman John Fraser takes over as interim chief executive effective June 17, 2026, while the board searches for a permanent CEO. Terms of Michael Buhle's separation agreement are not yet final. 2. 2026-06-05 Financings [Aspira Women's Health closes $1.485 million private placement](https://aibio.space/news/aspira-womens-health-closes-1-485-million-private-placement/) The June 5, 2026 deal sold 3,300,000 shares at $0.45 each, with warrants to buy up to 4,455,000 more shares. The filing names no underwriter or placement agent. 3. 2026-05-26 Company Updates [Aspira Women's Health expands Cleveland Clinic collaboration on AI diagnostics](https://aibio.space/news/aspira-womens-health-expands-cleveland-clinic-collaboration-ai/) The master collaboration and license agreement covers biomarker discovery, validation and analytical models for women's health diagnostics. The release states no financial terms. 4. 2026-04-26 Company Updates [Aspira Women's Health names John Strahley chief financial officer](https://aibio.space/news/aspira-womens-health-names-john-strahley-chief-financial-officer/) John Strahley joins as a fractional CFO and chief accounting officer effective April 27, 2026, on a $167,000 base salary, after the consulting arrangement with Brian Hungerford ended. 5. 2025-05-15 Distress [Aspira Women's Health delays first-quarter report to finish debt and equity accounting](https://aibio.space/news/aspira-womens-health-delays-first-quarter-report-finish-debt-equity/) Aspira says it needs more time to finish accounting for debt and equity deals from the first quarter, and it expects a smaller net loss helped by a milestone payment. 6. 2025-04-16 Listings [Nasdaq panel delists Aspira Women's Health over $2.5 million equity rule](https://aibio.space/news/nasdaq-panel-delists-aspira-womens-health-2-5-million-equity-rule/) Nasdaq's hearings panel has decided to delist Aspira Women's Health, which says its shares will trade on OTC markets under the symbol AWH. ## Aspira Women's Health at a glance - **Ticker**: AWHL - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $477,000 ### Related companies - [Tango Therapeutics](https://aibio.space/companies/tango-therapeutics/) NASDAQ: TNGX - [Cadrenal Therapeutics](https://aibio.space/companies/cadrenal-therapeutics/) NASDAQ: CVKD - [Neutra](https://aibio.space/companies/neutra/) OTC: NTRR - [Replimune Group](https://aibio.space/companies/replimune/) NASDAQ: REPL - [Mosaic ImmunoEngineering](https://aibio.space/companies/mosaic-immunoengineering/) OTC: CPMV - [Arvinas](https://aibio.space/companies/arvinas/) NASDAQ: ARVN - [Neurogene](https://aibio.space/companies/neurogene/) NASDAQ: NGNE - [Kailera Therapeutics](https://aibio.space/companies/kailera-therapeutics/) NASDAQ: KLRA ### Also on OTC - [Green Planet Bio Engineering Co.](https://aibio.space/companies/green-planet-bio-engineering/) GPLB - [Fresenius SE & Co. KGaA](https://aibio.space/companies/fresenius-fsnuy/) FSNUY - [Agentix](https://aibio.space/companies/agentix/) AGTX - [Calithera Biosciences](https://aibio.space/companies/calithera-biosciences/) CALA - [Inhibitor Therapeutics](https://aibio.space/companies/inhibitor-therapeutics/) INTI - [PONIARD PHARMACEUT](https://aibio.space/companies/poniard-pharmaceut/) PARD ## What Aspira Women's Health does Aspira Women's Health Inc. is dedicated to the discovery, development and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. It plans to broaden its focus to the differential diagnosis of other gynecologic diseases that typically cannot be assessed through traditional noninvasive clinical procedures. Its commercial OvaWatch test monitors adnexal masses through periodic testing at physician prescribed intervals. The OVAinform program is a multi-marker test that combines serum proteins, microRNA and clinical data to assess ovarian cancer risk. Its endometriosis program, ENDOinform, is a multi-marker test designed to aid the identification of endometriosis, which the text says affects approximately 10% of reproductive age women. The company owns and operates Aspira Labs, Inc., a CLIA certified laboratory in Texas. A contract from the Advanced Research Projects Agency for Health for ENDOinform was terminated in June 2025 after the company did not meet the specifications of the third milestone. The company says its current capital resources are not sufficient to fund its operations for the remainder of 2026. Its common stock began trading on the OTC Markets in April 2025 and is quoted on the OTC QX Best Market. | Product or program | What it is | Stage | |---|---|---| | OvaWatch | Monitors adnexal masses through periodic testing at physician prescribed intervals | Commercially available | | OVAinform | Multi-marker test combining proteins, miRNA and clinical data for ovarian cancer risk | Development program continues to progress | | ENDOinform | Multi-marker test combining serum proteins, miRNA and metadata to identify endometriosis | In development | Summarised from the company's [10-K filed Apr 1, 2026](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/awhl-20251231x10k.htm). ## Aspira Women's Health annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$343,000](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/) | [$4,000](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/) | | Research and development | [$2.9 million](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/) | [$3.3 million](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/) | | Net income (loss) | [-$12.8 million](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/) | [-$13.1 million](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/) | | Cash from operations | [-$7.0 million](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/) | [-$12.1 million](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/) | | Cash and equivalents | [$1.8 million](https://www.sec.gov/Archives/edgar/data/926617/000092661726000054/) | [$1.8 million](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $477,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Aspira Women's Health Was Aspira Women's Health delisted? Our latest story on this, dated Apr 16, 2025: "Nasdaq panel delists Aspira Women's Health over $2.5 million equity rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-panel-delists-aspira-womens-health-2-5-million-equity-rule/). Has Aspira Women's Health raised money recently? Our latest story on this, dated Jun 5, 2026: "Aspira Women's Health closes $1.485 million private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aspira-womens-health-closes-1-485-million-private-placement/). What is the ticker symbol of Aspira Women's Health? Aspira Women's Health Inc. trades under the ticker AWHL on OTC. Where is Aspira Women's Health listed? Aspira Women's Health Inc. is listed on OTC. What is the SEC CIK of Aspira Women's Health? The SEC Central Index Key (CIK) for Aspira Women's Health Inc. is 926617. Its filings are on SEC EDGAR. How many shares does Aspira Women's Health have outstanding? 46,633,744 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Aspira Women's Health listed under? Our directory records Aspira Women's Health Inc. under United States. What does Aspira Women's Health do? Our directory classifies Aspira Women's Health Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Aspira Women's Health? The ISIN recorded for Aspira Women's Health Inc. is US04537Y2081. Does aibio.space cover Aspira Women's Health? aibio.space lists Aspira Women's Health Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Aspira Women's Health incorporated? SEC records list its state or country of incorporation as DE. What does Aspira Women's Health develop? Aspira Women's Health Inc. is dedicated to the discovery, development and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. It plans to broaden its focus to the differential diagnosis of other gynecologic diseases that typically cannot be assessed through traditional noninvasive clinical procedures. What is OvaWatch from Aspira Women's Health? OvaWatch: Monitors adnexal masses through periodic testing at physician prescribed intervals Stage: Commercially available. What is OVAinform from Aspira Women's Health? OVAinform: Multi-marker test combining proteins, miRNA and clinical data for ovarian cancer risk Stage: Development program continues to progress. What was Aspira Women's Health's revenue last year? $343,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Aspira Women's Health Members talk about Aspira Women's Health (AWHL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Aspira Women's Health, newest first. Each line links the filing it comes from. 1. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/926617/000092661726000016/awhl-20251231xnt10k.htm) 2. 2025-12-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/926617/000110465925124245/awhl-20251223x8k.htm) 3. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/926617/000164117225011022/formnt10-q.htm) 4. 2025-04-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/926617/000164117225005086/ex99-1.htm) 5. 2025-04-11 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/926617/000164117225003902/formdef14a.htm) 6. 2025-03-31 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/926617/000164117225001869/formpre14a.htm) 7. 2025-02-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/926617/000149315225006890/form8-k.htm) 8. 2025-01-08 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/926617/000149315225001451/forms-1.htm) 9. 2024-12-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/926617/000149315224052755/form8-k.htm) 10. 2024-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/926617/000149315224045779/formnt10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:AWHL on TradingView](https://www.tradingview.com/symbols/OTC-AWHL/). ## SEC filings and registration - **SEC name**: Aspira Women's Health Inc. - **CIK**: 926617 - **Industry (SIC)**: In Vitro & In Vivo Diagnostic Substances (2835) - **US tickers**: AWHL (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 12117 BEE CAVES ROAD BUILDING THREE, AUSTIN, TX, 78738 - **Phone**: 512-519-0400 - **Shares outstanding**: 46,633,744 as of 2026-08-12 (10-Q filed 2026-08-14) - **Former names**: VERMILLION, INC.; CIPHERGEN BIOSYSTEMS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/926617/000092661726000054/awhl-20260630x10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/926617/000092661726000052/awhl-20260706x8k.htm) filed 2026-07-15 - [8-K](https://www.sec.gov/Archives/edgar/data/926617/000092661726000047/awhl-20260617x8k.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/926617/000092661726000045/awhl-20260617x8k.htm) filed 2026-06-17 - [8-K](https://www.sec.gov/Archives/edgar/data/926617/000092661726000042/awhl-20260529x8k.htm) filed 2026-06-09 - [8-K](https://www.sec.gov/Archives/edgar/data/926617/000092661726000037/awhl-20260520x8k.htm) filed 2026-05-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/926617/000092661726000033/awhl-20260331x10q.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/926617/000092661726000029/awhl-20260426x8k.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000926617), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Aspira Women's Health Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker AWHL, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Aspira Women's Health Inc. - **Ticker**: AWHL - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US04537Y2081 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-AWHL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/aspira-women-s-health/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aspira Women's Health (AWHL) news: delisting and offering", 2026-10-31, https://aibio.space/companies/aspira-women-s-health/